Lea este artculo en ingls aqu
Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
At a glance, the table underscores the throughline of this entire comparison: none of these three compounds substitutes for another, because each is anchored to a different level of biological activity cellular, mitochondrial, and endocrine, respectively
These reasons, while understandable from a procedural standpoint, can be clinically and emotionally detrimental to a patient with Pernicious Anemia who is symptomatic and in need of treatment
Archived from the original on August 7, 2024